Initial Clinical Experience With Regadenoson, a Novel Selective A2A Agonist for Pharmacologic Stress Single-Photon Emission Computed Tomography Myocardial Perfusion Imaging
Robert C. Hendel, MD*,1,2,*,
Timothy M. Bateman, MD1,2, ,
Manuel D. Cerqueira, MD1,2, ,
Ami E. Iskandrian, MD1, ,
Jeffrey A. Leppo, MD1,||,
Brent Blackburn, PhD¶ and
John J. Mahmarian, MD1,2,#
* Rush University Medical Center, Chicago, Illinois
Cardiovascular Consultants, Kansas City, Missouri
Cleveland Clinic, Cleveland, Ohio
University of Alabama at Birmingham, Birmingham, Alabama
|| Berkshire Medical Center, Pittsfield, Massachusetts
¶ CV Therapeutics, Palo Alto, California
# Methodist DeBakey Heart Center, The Methodist Hospital/Baylor College of Medicine, Houston, Texas

View larger version (10K):
[in a new window]
|
Figure 1 The molecular structure of regadenoson (CVT-3146; (1-{9-[(4S, 2R, 3R, 5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2yl]-6aminopurin-2-yl}pyrazol-4-yl)-N-methylcarboxamide).
|
|

View larger version (16K):
[in a new window]
|
Figure 2 Change in heart rate in beats/min (A) and in systolic blood pressure in mm Hg (B) from baseline after regadenoson administration; values are means with standard errors. Open squares = 400 µg; solid squares = 500 µg.
|
|

View larger version (141K):
[in a new window]
|
Figure 3 Direct comparison of adenosine and regadenoson images using a dual-isotope protocol (rest: thallium-201, stress: Tc-99m tetrofosmin). These images reveal a large, mild, reversible perfusion defect in the anterior, apical, and lateral walls. Similar findings were noted on the adenosine and regadenoson stress images. Upper panel is the regadenoson study.
|
|
|